---
title: "Craig-Hallum Keeps Their Buy Rating on Ligand Pharma (LGND)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295248352.md"
description: "Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Ligand Pharma (LGND) with a $370 price target. Hewitt, who covers the healthcare sector, has a 47.4% success rate. This contrasts with the broader market consensus, which suggests a Strong Buy rating for LGND with an average price target of $355.13."
datetime: "2026-08-07T14:06:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295248352.md)
  - [en](https://longbridge.com/en/news/295248352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295248352.md)
generator: "portal-rs"
---

# Craig-Hallum Keeps Their Buy Rating on Ligand Pharma (LGND)

In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Ligand Pharma, with a price target of $370.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Hewitt covers the Healthcare sector, focusing on stocks such as MaxCyte, Ligand Pharma, and Codexis. According to TipRanks, Hewitt has an average return of 3.4% and a 47.40% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ligand Pharma with a $355.13 average price target.

### Related Stocks

- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [MXCT.US](https://longbridge.com/en/quote/MXCT.US.md)
- [CDXS.US](https://longbridge.com/en/quote/CDXS.US.md)

## Related News & Research

- [If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/297831679.md)
- [Is Ligand Pharmaceuticals (LGND) Undervalued On Its Conference Appearance?](https://longbridge.com/en/news/297426603.md)
- [Ranger Investment Management L.P. Acquires Shares of 257,596 Ligand Pharmaceuticals Incorporated $LGND](https://longbridge.com/en/news/296772770.md)
- [Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance](https://longbridge.com/en/news/297061481.md)
- [$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296632631.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**